What is a common treatment approach for patients with wet AMD?

The most commonly used treatment approach for patients with wet age-related macular degeneration (AMD) is the administration of anti-VEGF injections. This treatment targets the vascular endothelial growth factor (VEGF), a protein that promotes the growth of abnormal blood vessels in the retina, which is characteristic of wet AMD. By inhibiting VEGF, these injections help reduce the leakage of fluid and swelling in the retina, effectively stabilizing and sometimes improving vision for affected patients.

Anti-VEGF therapies, such as ranibizumab (Lucentis), aflibercept (Eylea), and bevacizumab (Avastin), have been shown to be highly effective in clinical trials, leading to significant improvements in visual acuity and overall retinal health. This treatment strategy has become the standard of care for managing wet AMD due to its efficacy and the relatively straightforward administration process.

The other treatment options have their uses but are not the first-line treatments for wet AMD. For example, vitrectomy is typically reserved for tractional retinal detachment or other vitreoretinal disorders rather than wet AMD. Laser photocoagulation can be used in some cases of wet AMD, particularly for treatable lesions, but it is less common now due to